Tuberculosis Screening, Testing, and Treatment of U.S. Health Care Personnel: Recommendations from the National Tuberculosis Controllers Association and CDC, 2019.


Journal

MMWR. Morbidity and mortality weekly report
ISSN: 1545-861X
Titre abrégé: MMWR Morb Mortal Wkly Rep
Pays: United States
ID NLM: 7802429

Informations de publication

Date de publication:
17 May 2019
Historique:
entrez: 18 5 2019
pubmed: 18 5 2019
medline: 22 5 2019
Statut: epublish

Résumé

The 2005 CDC guidelines for preventing Mycobacterium tuberculosis transmission in health care settings include recommendations for baseline tuberculosis (TB) screening of all U.S. health care personnel and annual testing for health care personnel working in medium-risk settings or settings with potential for ongoing transmission (1). Using evidence from a systematic review conducted by a National Tuberculosis Controllers Association (NTCA)-CDC work group, and following methods adapted from the Guide to Community Preventive Services (2,3), the 2005 CDC recommendations for testing U.S. health care personnel have been updated and now include 1) TB screening with an individual risk assessment and symptom evaluation at baseline (preplacement); 2) TB testing with an interferon-gamma release assay (IGRA) or a tuberculin skin test (TST) for persons without documented prior TB disease or latent TB infection (LTBI); 3) no routine serial TB testing at any interval after baseline in the absence of a known exposure or ongoing transmission; 4) encouragement of treatment for all health care personnel with untreated LTBI, unless treatment is contraindicated; 5) annual symptom screening for health care personnel with untreated LTBI; and 6) annual TB education of all health care personnel.

Identifiants

pubmed: 31099768
doi: 10.15585/mmwr.mm6819a3
pmc: PMC6522077
doi:

Types de publication

Journal Article Practice Guideline

Langues

eng

Sous-ensembles de citation

IM

Pagination

439-443

Déclaration de conflit d'intérêts

All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. Wendy Thanassi reports a grant from Qiagen Inc. outside the submitted work. Lorna Will reports personal fees from the National Tuberculosis Controllers Association during the conduct of the study. MaryAnn Gruden reports personal fees from the Allegheny Health Network, Association of Occupational Health Professionals in Healthcare, and National Institute for Occupational Safety and Health Board of Scientific Counselors outside the submitted work. No other potential conflicts of interest were disclosed.

Références

Am J Prev Med. 2000 Jan;18(1 Suppl):35-43
pubmed: 10806978
Am J Prev Med. 2000 Jan;18(1 Suppl):44-74
pubmed: 10806979
MMWR Recomm Rep. 2005 Dec 30;54(RR-17):1-141
pubmed: 16382216
Thorax. 2012 Jan;67(1):62-70
pubmed: 21228420
Infect Control Hosp Epidemiol. 2012 Nov;33(11):1126-32
pubmed: 23041811
Am J Respir Crit Care Med. 2014 Jan 1;189(1):77-87
pubmed: 24299555
Clin Infect Dis. 2017 Jan 15;64(2):111-115
pubmed: 28052967
Lancet Infect Dis. 2017 Oct;17(10):e327-e333
pubmed: 28495525
BMC Med. 2017 May 17;15(1):104
pubmed: 28514962
Clin Infect Dis. 2018 Feb 10;66(5):706-711
pubmed: 29028965
MMWR Morb Mortal Wkly Rep. 2018 Mar 23;67(11):317-323
pubmed: 29565838

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH